PA, NJ, DE-Israel Life Sciences Conference

Israeli Company Survey

We look forward to your participation in the in the PA, NJ, DE-Israel Life Sciences Conference.

To help ensure that the program meets your needs and is attended by appropriate representatives from the life sciences industry, funding organizations and other strategic partners from our region that are well-matched to your business, AICC is seeking your input.

Please respond to this questionnaire and return it to the Israel Export Institute at (add contact information) no later than Aug 14th, 2008.

  1. Key Contact’s Information
  2. Company Name: SteadyMed Ltd.
  3. Company Technology: Device,
    Biotechnology,
    Pharmaceuticals,
    Healthcare IT
  4. Company Site: www.steadymed.com
  5. Delegate’s Name: Yossi Aldar
  6. Delegate’s Title: CEO
  7. Delegate’s Phone: 972-54-6611222
  8. Company description and background and current financials - including investments. (50 word limit)

SteadyMed is an Israeli medical device company developing proprietary products based on its patented drug-delivery technology. The company was founded in June 2005 and has raised $1m so far, almost all dedicated to R&D, patenting and initial business development.

  1. Product description including, target market, stage of development and major accomplishments to date (50 word limit)

SteadyMed is developing a miniature patch-type delivery device for injectable drugs - the PatchPump. This product addresses unmet needs in delivery of biologics and viscous drugs and will serve as a smart-package for delivering such therapies in the home. The company has developed and proven its technology plaform, and now seeks to advance towards partnering and commercialization.

  1. Are you seeking an investment? Y/N
  2. Amount $5m
  3. Timeframe: 6 months
  4. Purpose: Partnering and Commercialization
  5. Preferred Source: Financial Investors
  6. Listed below is a sampling of the key Life-Science constituents in our area. Based on your research, please identify all the organizations (whether or not listed) that you believe are appropriate prospects for a strategic partnership with your company.
  7. For each company, please tell us what division or department within the company is best suited to a collaboration with your company
  8. For each department, please identify the title of the most appropriate contact for your meeting (examples-Director of R&D, Global Business Development, Medical Specialist, Licensing Officer)

Arrow International:

AstraZeneca Pharmaceuticals LP: GBD

Baxter Healthcare Corp: GBD

Bristol-Myers Squibb Co.: GBD

Cephalon Inc.: GBD

Covatec:

ENDO Pharmaceuticals: GBD

Genzyme Corp.: GBD

GlaxoSmith-Kline: GBD

Impax Laboratories Inc.:

Johnson& Johnson

Centocor Biologics: GBD

Ethicon LLC:

Janssen Pharmaceutical Inc: GBD

McNEIL-PPC Inc.:

Ortho BioTech Inc.:

Ortho Clinical Diagnostics:

Lannett Co. Inc.: GBD

Laron Pharmaceuticals Inc.:

Mennen Medical Corp.:

Merck & Co Inc.: GBD

Kensey Nash Corp.:

Novartis Pharmaceuticals Corp.: GBD

Pfizer Inc.: GBD

Quest Diagnostics:

Roche

Pharmaceuticals: GBD

Diagnostics:

Sanofi Aventis:

Shire US Inc.:

Siemens Medical Solutions:

ViroPharma Inc.:

West Pharmaceutical Services:

Wyeth Pharmaceuticals: GBD

Zlb Behring LLC:

  1. From the list below, please provide all additional areas for potential collaboration and resource development for your company.
  2. Physicians/Health care practitioners
  3. Reimbursement
  4. Regulatory Issues
  5. Clinical Trials
  6. Healthcare Administrators
  7. Distribution
  8. Technology transfer
  9. Academia
  10. Incubators/Science Parks
  11. Licensing
  12. Medical Advisory
  13. Financial Advisory
  14. Clinical Development
  15. Intellectual Property
  16. Staffing
  17. Others (please list)